Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells.

Ding Y, Chen X, Liu C, Ge W, Wang Q, Hao X, Wang M, Chen Y, Zhang Q. · 2021

Read Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells. by Ding Y, Chen X, Liu C, Ge W, Wang Q, Hao X, Wang M, Chen Y, Zhang Q. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7816340.txt.

Introduction

Ding and co-authors identify a small molecule that kills triple negative breast cancer cells in two ways. This cancer type is the most aggressive breast cancer. It recurs more and kills more than other types. New drugs with fresh modes of action are badly needed.

The molecule triggers ferroptosis, an iron-driven form of cell death. It also triggers apoptosis, the classic cell suicide path. It works by tagging the protein GPX4 for removal. GPX4 normally shields cells from ferroptosis. Losing it leaves cancer cells open to both death routes. The authors screened drug candidates to find this compound. They present it as a lead for new TNBC therapy.

Catalog record

CREATORDing Y, Chen X, Liu C, Ge W, Wang Q, Hao X, Wang M, Chen Y, Zhang Q.
YEAR2021
COLLECTIONPAPERS
FORMATTXT
FILE SIZE74 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7816340

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells By Yahui Ding, Xiaoping Chen, Can Liu, Weizhi Ge, Qin Wang, Xin Hao, Mengmeng Wang, Yue Chen, Quan Zhang Published in: Journal of Hematology & Oncology DOI: 10.1186/s13045-020-01016-8 ABSTRACT Abstract Background TNBC is the most aggressive breast cancer with higher recurrence and mortality rate than other types of breast cancer. There is an urgent need for identification of therapeutic agents with unique mode of action for overcoming current challenges in TNBC treatment. Methods Different inhibitors were used to study the cell death manner of DMOCPTL. RNA silencing was used to evaluate the functions of GPX4 in ferroptosis and apoptosis of TNBC cells and functions of EGR1 in apoptosis. Immunohistochemical assay of tissue microarray were used for investigating correlation of GPX4 and EGR1 with TNBC. Computer-aided docking and small molecule probe were used for study the binding of DMOCPTL with GPX4. Results DMOCPTL, a derivative of natural product parthenolide, exhibited about 15-fold improvement comparing to that of the parent compound PTL for TNBC cells. The cell death manner assay showed that the anti-TNBC effect of DMOCPTL mainly by inducing ferroptosis and apoptosis through ubiquitination of GPX4. The probe of DMOCPTL assay indicated that DMOCPTL induced GPX4 ubiquitination by directly binding to GPX4 protein. To the best of our knowledge, this is the first report of inducing ferroptosis through ubiquitination of GPX4. Moreover, the mechanism of GPX4 regulation of apoptosis is still obscure. Here, we firstly reveal that GPX4 regulated mitochondria-mediated apoptosis through regulation of EGR1 in TNBC cells. Compound 13, the prodrug of DMOCPTL, effectively inhibited the growth of breast tumor and prolonged the lifespan of mice in vivo, and no obvious toxicity was observed. Conclusions These findings firstly revealed novel manner to induce ferroptosis through ubiquitination of GPX4 and provided mechanism for GPX4 inducing mitochondria-mediated apoptosis through up-regulation of EGR1 in TNBC cells. Moreover, compound 13 deserves further studies as a lead compound with novel mode of action for ultimate discovery of effective anti-TNBC drug. Keywords: GPX4, Ubiquitination, EGR1, Ferroptosis, Triple negative breast cancer INTRODUCTION Ferroptosis is a new form of programmed cell death characterized by the accumulation of iron-dependent lipid peroxides, and is morphologically, biochemically, and genetically distinct from apoptosis, necrosis, and autophagy [1]. In recent years, more and more research revealed that ferroptosis was implicated in various human diseases, including Alzheimer’s, Parkinson’s and Huntington’s diseases, stroke, periventricular leukomalacia (PVL), intracerebral hemorrhage, kidney degeneration [2, 3]. Moreover, emerging evidence indicated that ferroptosis may also have a tumor-suppressor function for cancer therapy. It was reported that many cancer cells, such as liver cancer, diffuse large B cell lymphomas (DLBCL), renal cell carcinoma, gastric cancer, rhabdomyosarcoma, ovarian cancer cells, are susceptible to ferroptosis [4, 5]. Small molecule ferroptosis inducers had a strong inhibition of tumor growth and enhanced the sensitivity of chemotherapeutic drugs [6]. Combination of chemotherapeutic drugs such as tmozolomide, cisplatin, doxorubicin with ferroptosis inducer erastin resulted in a remarkable synergistic effect on tumor treatment [3]. Therefore, induction of ferroptosis has become a novel potential therapeutic strategy for cancer therapy [7–12]. Breast cancer is the most commonly being diagnosed cancer and the leading cause of cancer death for women. Worldwide, there are about 2.1 million newly diagnosed female breast cancer cases, and the incidence and mortality of female breast cancer is 24.2% and 15%, respectively, in 2018 [13]. Breast cancer accounts for 30% all new cancer diagnoses in women in USA [14]. Although 5-year relative survival rate for breast cancer is 90% in USA [14], the prognosis is still far from satisfactory, especially for triple-negative breast cancer (TNBC). TNBC is the most aggressive breast cancer with higher recurrence and mortality rate than other types of breast cancer [15]. TNBC represents 15–20% of breast carcinomas and is characterized by lack of expression of estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptor 2 (HER-2) [16, 17]. TNBC patients cannot benefit from targeted therapy, such as endocrine or anti-HER2 therapy and chemotherapy is still the only validated therapy option for treatment of TNBC in clinical practice [18]. Therefore, there is an urgent need for identification of therapeutic agents with unique mode of action for overcoming current challenges in TNBC treatment. It was reported that ferroptosis inducer erastin could selectively target MDA-MB-231 cells and efficiently induce ferroptosis in TNBC cells [19]. Sulfasalazine could induce ferroptosis in breast cancer cells with low ER expression [20]. Combination of siramesine and lapatinib induced ferroptosis in MDA-MB-231 and SKBR3 cells [21]. Kufe et al., identified that targeting MUC1-C/xCT signaling pathway induced ferroptosis of TNBC cells [22]. Lee and Tseng et al., reported that cystine starvation could trigger ferroptosis through CHAC1 degradation of glutathione via GCN2-eIF2α-ATF4 pathway in human TNBC cells [23]. Therefore, inducing ferroptosis is a new effective strategy for treatment of TNBC. Sesquiterpene lactones (SLs) have attracted extensive attention because of their potent bioactivity, such as anti-cancer, anti-inflammatory and anti-malaria [24, 25]. Parthenolide (1, PTL, Fig. 1), a prominent germacrane-type SL, showed promising anti-cancer property. Nevertheless, PTL has some disadvantages, such as poor oral bioavailability, unstable under chemical and physiological conditions and poor water solubility [26, 27]. DMAPT, a derivative of PTL, effectively increased the water solubility and oral bioavailability, which has advanced into a phase I clinical trial for treatment of acute myeloid leukemia (AML) [25]. Recently, we developed the other PTL derivative, ACT001, to be in clinical trial in Australia and China for treatment of glioblastoma [28]. [Figure: Structures of parthenolide (1), DMAPT, and ACT001] As previous studies suggested that GPX4 inhibition induced ferroptosis [29], we rationalized that an alternative way to lead to cancer cell death by inducing ferroptosis would be through ubiquitination of GPX4 to reduce abundance of GPX4. In this study, we revealed a PTL derivative (2, DMOCPTL, Fig. 2) as an inducer of ferroptosis and apoptosis through ubiquitination of GPX4 and a potential therapeutic agent for TNBC. To the best our knowledge, herein, this is the first report of inducing ferroptosis through ubiquitination of GPX4. [Figure: The antiproliferative activity of DMOCPTL in TNBC cells. a The chemical structure of DMOCPTL. b The effect of DMOCPTL on the viability of MDA-MB-231 and SUM159 cells after being treated for 72 h. c The representative pictures and colony number of MDA-MB-231 and 4T1 cells after treatment of DMOCPTL at concentrations of 0.05 μM, 0.1 μM and 0.25 μM, respectively. d The effect of DMOCPTL and PTL at a concentration of 0.5 μM on colony formation in MDA-MB-231 cells. Analysis results represented mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001] MATERIALS AND METHODS Chemistry Synthesis of compound 4. To a solution of 3 (500 mg, 2.74 mmol) and TBSCl (455 mg, 3.0 mmol) in CH2Cl2 was added imidazole (204 mg, 3.0 mmol) at 0 °C. The mixture was stirred overnight, quenched with NH4Cl, and extracted with CH2Cl2. The CH2Cl2 layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure to provide 4 (731 mg, 2.47 mmol, yield 90%). Synthesis of compound 5. To a solution of trimethyl phosphonoacetate (1.48 mL, 9.17 mmol) in anhydrous THF (20 mL) was added LiHMDS (1.0 M, 9.17 mL, 9.17

Read the complete text